


JFW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Confirmation No.: 2640

BRASLAWSKY et al.

Group Art Unit: 1654

Application No. ~~10/796,958~~ 10/796,158 Examiner: Marcel M. Cordero Garcia, Ph.D.

Filed: March 10, 2004

Title: THIOL-MEDIATED DRUG ATTACHMENT TO TARGETING PEPTIDES

\* \* \* \* \*

**ELECTION RESPONSE**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This is in response to the official communication [restriction requirement] mailed on October 19, 2005. Applicants elect, without traverse, claims 15-20 of **Group III**, which are directed to methods of treating an SSTR-associated disorder. For the purposes of examination, applicants further elect the somatostatin analog wherein A is SEQ ID NO:1 (claim 16), and B is SEQ ID NO:4 (claim 17). This is the CP1 somatostatin analog of SEQ ID NO:5 (claim 18). Upon allowance generic claim 15, it is requested that the non-elected species of additionally disclosed somatostatin analogs be considered.

If there are any questions regarding the above, applicants respectfully request that the examiner contact the undersigned attorney.

Respectfully submitted,

PILLSBURY WINTHROP SHAW PITTMAN LLP

Thomas A. Cawley, Jr., Ph.D.  
Registration No. 40,944

P.O. Box 10500  
McLean, VA 22102  
(703) 770-7944 Direct Dial  
(703) 770-7901 Facsimile  
November 21, 2005  
TAC/JBM